{
  "id": 19240815,
  "title": "Becton Dickinson chairman, CEO Polen sells $4.25 million in stock",
  "url": "https://urgent.news/2026/11/09/becton-dickinson-chairman-ceo-polen-sells-4-25-million-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T23:16:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/becton-dickinson-chairman-ceo-polen-sells-425-million-in-stock-93CH-5013682"
  },
  "original_language": "en",
  "account": null,
  "summary": "Becton Dickinson Chairman and CEO Thomas E. Polen Jr. sold 20,239 shares of company stock worth $4.25 million on November 5, 2026, as part of a pre-approved trading plan. The sale was accompanied by the exercise of 20,239 stock appreciation rights (SARs), which resulted in the acquisition of the same number of shares at an exercise price of $178.94 per share. These transactions were facilitated by the adjustment of SAR terms due to the embecta spinoff and the combination of Becton Dickinson's Biosciences and Diagnostic Solutions businesses with Waters Corp. The company recently reported strong fiscal fourth-quarter results, with earnings per share at $4.15 and revenue of $5.3 billion, surpassing Wall Street's expectations. Following these developments, investment firms Jefferies and Wells Fargo raised their price targets for Becton Dickinson to $242, reflecting confidence in the company's future performance.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}